MAZE THERAPEUTICS, INC. Employee Count
The employee counts MAZE THERAPEUTICS, INC. states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 141; Filing 2026-03-25; Lease expense per employee $35,985.82.
- 2024-12-31: Employees (as filed) 125; Filing 2025-03-31; Lease expense per employee $40,592.00.
- Available history
- 2024-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 141 full-time | 2026-03-25 | $35,985.82 operating |
| 2024-12-31 | 125 full-time | 2025-03-31 | $40,592.00 operating |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |